Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.63 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 8/20 | 0.51 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4744393 | 0.87 | MAOB (0.64) | HRH3BRD4MAOBMAOA | |
| SCHEMBL979739 | 0.86 | HRH3 (0.64) | HRH3BRD4MAOBMAOAPBRM1 | |
| SCHEMBL16471646 | 0.85 | HRH3 (0.63) | HRH3BRD4MAOBMAOAPBRM1 | |
| SCHEMBL12921977 | 0.85 | BRD4 (0.66) | HRH3BRD4MAOBMAOA | |
| SCHEMBL15085354 | 0.84 | BRD4 (0.69) | HRH3BRD4MAOBMAOA | |
| SCHEMBL8651866 | 0.84 | BRD4 (0.64) | HRH3BRD4MAOBMAOA | |
| SCHEMBL9948198 | 0.83 | HRH3 (0.64) | HRH3BRD4MAOBMAOAPBRM1 | |
| SCHEMBL12525843 | 0.82 | HRH3 (0.63) | HRH3BRD4MAOBMAOA | |
| SCHEMBL7398994 | 0.82 | MAOB (0.62) | HRH3BRD4MAOBMAOA | |
| SCHEMBL8652023 | 0.81 | BRD4 (0.65) | HRH3BRD4MAOBMAOAPBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872132-B2 | Intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-18 | — | — | US | disclosed |
| US-7872132-B2 | Intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-18 | — | — | US | disclosed |
| CN-101068789-B | Novel intermediate for preparing aripiprazole, preparation method thereof, and preparation method of aripiprazole | SUVEN LIFESCIENCES LTD | 2010-12-15 | — | — | CN | disclosed |
| US-20090203907-A1 | Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| US-20090203907-A1 | Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| US-20080299216-A1 | DEUTERIUM-ENRICHED ARIPIPRAZOLE | PROTIA, LLC (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080299216-A1 | DEUTERIUM-ENRICHED ARIPIPRAZOLE | PROTIA, LLC (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1812395-B1 | METHOD FOR THE PREPARATION OF ARIPIPRAZOLE, AND CORRESPONDING INTERMEDIATES AND THEIR PREPARATION | SUVEN LIFE SCIENCES LTD (IN) | 2008-05-21 | — | — | EP | disclosed |
| CN-101068789-A | Novel intermediate for preparing aripiprazole, preparation method thereof, and preparation method of aripiprazole | SUVEN LIFESCIENCES LTD (IN) | 2007-11-07 | — | — | CN | disclosed |
| EP-1812395-A1 | METHOD FOR THE PREPARATION OF ARIPIPRAZOLE, AND CORRESPONDING INTERMEDIATES AND THEIR PREPARATION | Suven Life Sciences Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006038220-A1 | NOVEL INTERMEDIATES USEFUL FOR THE PREPARATION OF ARIPIPRAZOLE AND METHODS FOR THE PREPARATION OF THE NOVEL INTERMEDIATES AND ARIPIPRAZOLE | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006038220-A1 | NOVEL INTERMEDIATES USEFUL FOR THE PREPARATION OF ARIPIPRAZOLE AND METHODS FOR THE PREPARATION OF THE NOVEL INTERMEDIATES AND ARIPIPRAZOLE | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203907-A1 | Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | CYP2J2, CYP2B6, CYP2C19 | HRH3 431/4885BRD4 339/4885MAOB 328/4885 |
| US-20080299216-A1 | DEUTERIUM-ENRICHED ARIPIPRAZOLE | SLC6A3, AASDHPPT, MC2R | HRH3 266/4885BRD4 216/4885MAOB 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.